DS
ADCT icon

David Shaw’s ADC Therapeutics ADCT Stock Holding History

David Shaw’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$770K Buy
719,320
+476,144
+196% +$1.39M ﹤0.01% 3929
2026
Q1 		$912K Sell
243,176
-19,895
-8% -$78.4K ﹤0.01% 3499
2025
Q4 		$929K Buy
+263,071
New +$1.07M ﹤0.01% 3596
2024
Q4 		– Sell
-284,243
Closed -$895K – 4357
2024
Q3 		$895K Buy
284,243
+20,531
+8% +$64.7K ﹤0.01% 3357
2024
Q2 		$833K Buy
263,712
+236,791
+880% +$941K ﹤0.01% 3298
2024
Q1 		$121K Buy
+26,921
New +$99.3K ﹤0.01% 3990
2020
Q4 		– Sell
-27,713
Closed -$914K – 3872
2020
Q3 		$914K Buy
+27,713
New +$1.2M ﹤0.01% 2918

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

David Shaw's ADCT Position: Q2 2026 in Review

David Shaw increased its ADC Therapeutics (ADCT) stake by 196% in Q2 2026, buying an estimated $1.39M and bringing the position to 719,320 shares worth $770K. The position accounts for ﹤0.01% of the portfolio, ranked #3929.

David Shaw first reported a position in ADCT in Q3 2020 and has held it in 7 quarters since. The position peaked at $929K in Q4 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • David Shaw held 719,320 shares of ADC Therapeutics worth $770K as of Q2 2026.
  • David Shaw bought 476,144 ADC Therapeutics shares in Q2 2026, an estimated $1.39M.
  • ADC Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3929 holding.
  • David Shaw first reported a position in ADC Therapeutics in Q3 2020 and has held it in 7 quarters since.
  • David Shaw's ADC Therapeutics position peaked at $929K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.